Corcept Therapeutics (NASDAQ:CORT) is my favorite type of biotech company. It has an approved, marketed product with ramping sales, promising pipeline candidates, and is beginning to turn a profit. Both guidance by the company and analyst coverage suggest substantial growth in earnings and revenue. While not without the inherent risks of investing in a small/mid-cap biotech companies, I believe that Corcept is an attractive, long-term investment at current levels. Before CORT announces its latest quarterly and year-end results, now is a good time to investigate this company further.
About the Company
Corcept was founded in 1998 and has focused on the effects of an overabundance of cortisol as well as the potential benefits of developing glucocorticoid receptor antagonists (GRAs). Approximately 80 percent of the body’s tissues have receptors for cortisol. Excess cortisol can be life-threatening if not treated effectively. In February of 2012, the FDA approved Korlym (mifepristone) for a once-daily oral dose to treat hyperglycemia secondary to hypercortisolism, excess cortisol, in adult patients with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or surgery has failed.
Hot Biotech Stocks To Watch For 2019: ArQule Inc.(ARQL)
- [By Stephan Byrd]
ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.
Hot Biotech Stocks To Watch For 2019: Amgen Inc.(AMGN)
- [By Brian Feroldi]
The study in questionis called ADVANCE. This phase 3 trial was designed to demonstrate noninferiority of Spectrum’s drug Rolontis when compared to Amgen’s (NASDAQ:AMGN) megablockbuster drug Neulasta in patients with early-stage breast cancer.
- [By Chris Lange]
And Amgen Inc. (NASDAQ: AMGN) will report its most recent quarterly results late Thursday. The consensus forecast is $3.24 in EPS and $5.43 billion in revenue. Shares closed on Friday at $171.56, in a 52-week range of $152.16 to $201.23. The consensus price target is $195.14.
- [By ]
For example, if you buy 100 shares of theNasdaq100ETF(NYSE: QQQ), you’re theoretically buying 11.9 shares of Apple (NASDAQ: AAPL)… 7.7 shares of Facebook (NASDAQ: FB)… 1.8 shares ofAmgen(NASDAQ: AMGN)… 2.6 shares of Comcast (NASDAQ: CMCSA)… and even smaller amounts of about 95 different companies.
- [By ]
This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV) , Amgen (AMGN) , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN) and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days,” according to Real Money Pro columnist Bret Jensen.
Hot Biotech Stocks To Watch For 2019: Alnylam Pharmaceuticals Inc.(ALNY)
- [By Brian Orelli]
The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”
- [By Keith Speights]
I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick — but with a couple of qualifications. First, I didn’t think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.
- [By Max Byerly]
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.
- [By Brian Orelli]
Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.
Hot Biotech Stocks To Watch For 2019: Biogen Idec Inc(BIIB)
- [By ]
What should investors do with shares of Celgene (CELG) , Biogen Idec (BIIB) , Gilead Science (GILD) and Regeneron (REGN) ? Cramer once proclaimed these high-fliers his “four horsemen of biotech,” but lately they’ve lost all of their traction, with Celgene down 21%, Biogen off 14%, Gilead down 9% and Regeneron off 23% so far this year.
- [By Keith Speights]
This has been a bad year for Biogen (NASDAQ:BIIB) so far — the biotech’s stock has dropped more than 10% since it began. But 2018 has been horrible for Acadia Pharmaceuticals (NASDAQ:ACAD), which has seen its share price plunge nearly 40%.
- [By Garrett Baldwin]
Markets are keeping a close eye on the 10-year bond, which is hovering near 3% – an important psychological level that is likely to influence future price movements. On Monday, Fox Business Network’s “Varney & Co.” asked Money Morning Chief Investment Strategist Keith Fitz-Gerald if investors should be worried. Here’s what Keith had to say about the 10-year Treasury yield… and how it will affect your stocks and bonds in the future.
The price of Brent crude oil topped $75.00 and hit its highest level since November 2014. Oil traders were eyeing the ongoing efforts of OPEC and Russia to reduce excessive production around the globe, rising demand ahead of peak driving season, and the possibility that the Trump administration will slap Iran with a new round of sanctions.
Three Stocks to Watch Today: KO, GOOGL, SLM
Shares of The Coca-Cola Co.(NYSE: KO) added 1.2% after the firm easily beat earnings and revenue expectations. The firm cited strong demand for its new flavors of Diet Coke and its Coke Zero Sugar. Demand was so strong for the quarter that the firm reported organic sales growth of 5%. The company reported earnings per share of $0.47, topping estimates by a penny. Revenue of $7.6 billion easily beat Wall Street estimates.
Shares of Alphabet Inc. (Nasdaq: GOOGL) seesawed in pre-market hours. The online search giant topped Wall Street earnings and revenue expectations after the bell Monday. However, shares were off 0.5% after executives announced that its business costs were on the rise. The firm’s real estate and computer purchases tripled in one year, to $7.3 billion. About one-third of that total came from its $2.4 billion purchase of the Chelsea Market building in New York City.
Good news for SLM Corp.(NYSE: SLM) investors, but bad news for indebted college students and graduates. The firm – also known as Sallie Mae – topped Wall Street earnings expectations on Monday. The firm said that it increased its loan o
- [By Joseph Griffin]
Here are some of the news stories that may have effected Accern’s analysis:
Get Biogen alerts:
Biogen (BIIB) Expected to Post Quarterly Sales of $3.24 Billion (americanbankingnews.com) Biogen Inc (NASDAQ:BIIB): Does The Earnings Decline Make It An Underperformer? (finance.yahoo.com) 5 Trade Ideas For Monday: AMTD, BIIB, DEO, FITB, TECK (investing.com) $5.29 EPS Expected for Biogen (BIIB) This Quarter (americanbankingnews.com) Biogen (BIIB) Upgraded by ValuEngine to “Hold” (americanbankingnews.com)
Shares of Biogen traded up $5.45, reaching $281.51, during midday trading on Wednesday, according to MarketBeat Ratings. 1,514,169 shares of the company’s stock were exchanged, compared to its average volume of 1,729,786. Biogen has a 52-week low of $276.94 and a 52-week high of $281.57. The firm has a market cap of $59.58 billion, a price-to-earnings ratio of 12.91, a PEG ratio of 1.65 and a beta of 0.84. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.95 and a current ratio of 3.23.